Protillion Biosciences is a Stanford University spinout commercializing a platform for therapeutic antibody and binder discovery. The company's technology enables commercial drug discovery partners to perform quantitative analysis on complete protein libraries and produce actionable insights in days. Protillion's proprietary platform can generate and analyze massive experimental datasets at perfect amino acid resolution, enabling novel machine-learning approaches to antibody and binder discovery. Led by co-founder and CEO Curtis Layton, Ph.D., and developed with co-founder William Greenleaf, Ph.D., the company also counts David Walt, Ph.D., on its board. Launched in 2019 and based in Burlingame, California, Protillion intends to use the Series A proceeds to scale its hardware infrastructure and development teams. The company raised $18M in Series A financing led by ARCH Venture Partners and Illumina Ventures.

Total raised

$18M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2022